Vaxess Technologies, Inc.
Cambridge, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 790 Memorial Dr #200, Cambridge, MA 02139, USA
- Website
- vaxess.com
- Founded
- 2011
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Vaxess Technologies, Inc., registered in SAM.gov since 2012, is a biotechnology company specializing in innovative microneedle array patch (MAP) technologies for medical and vaccine delivery. The company develops advanced drug and vaccine delivery platforms utilizing silk fibroin biomaterials, focusing on creating needle-free, shelf-stable, and self-applicable therapeutic solutions. As a self-certified small disadvantaged business and for-profit organization, Vaxess Technologies has demonstrated capabilities in developing cutting-edge pharmaceutical delivery systems across multiple medical domains.
Regarding federal contract awards, Vaxess Technologies has one notable contract with the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The $749,000 contract, awarded in August 2020, focused on manufacturing up to 100 million shelf-stable, self-applied single-dose COVID-19 vaccine patches. The contract, which ran through June 30, 2021, was part of a pandemic response effort seeking host-directed therapeutic candidates. No specific set-aside designations or subcontractors were indicated for this contract, and the award supported the company's advancement of its MIMIX-COVID pre-fusion spike protein vaccine patch through safety review and Phase I clinical trials.
In terms of federal grant awards, Vaxess Technologies has received multiple significant grants from different federal agencies. The National Institute of Diabetes and Digestive and Kidney Diseases awarded a $335,410 grant to develop a microneedle array patch for delivering GLP-1 receptor agonist to treat type 2 diabetes. The National Institute of Allergy and Infectious Diseases provided funding for a microarray patch project aimed at creating a broadly protective seasonal influenza vaccination. Additionally, the National Science Foundation supported a Phase I SBIR grant for an at-home, single-dose mRNA vaccine patch for COVID-19. The company also received a sub-grant from Baylor College of Medicine, demonstrating expertise in silk matrix processing, formulation, and stability assessment. These grants collectively showcase Vaxess Technologies' focus on innovative, needle-free therapeutic delivery systems across various medical conditions.
Quick answers
Is Vaxess Technologies, Inc. registered in SAM.gov?
Yes. Vaxess Technologies, Inc.'s SAM.gov registration is active through January 5, 2027.
What is Vaxess Technologies, Inc.'s CAGE code?
Vaxess Technologies, Inc.'s CAGE code is 6SPN3, and its Unique Entity ID (UEI) is HNLJN8YZPVJ3.
What is Vaxess Technologies, Inc.'s most recent federal award?
Vaxess Technologies, Inc.'s most recent federal grant award is Development of a needle free microarray patch for delivery of a GLP-1 receptor agonist (R43DK142429), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 16, 2024.
On GovTribe
See Vaxess Technologies, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors